We are evaluating the safety and effectiveness of Etentamig for individuals with Light Chain Amyloidosis. This study aims to understand how well this treatment works for managing the disease.
Health conditions and diseases that the clinical trial is designed to study and treat.
Light Chain Amyloidosis (AL Amyloidosis) is a rare disease caused by the buildup of abnormal proteins called light chains in the body, which can affect organs such as the heart, kidneys, and liver, leading to serious health complications.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
